MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Efficacy of Audiovisual Neuromodulation in the Treatment of Parkinson’s Disease

    O. Alenikova, L. Parkhach, E. Bоsiakova, G. Zobnina (Minsk, Belarus)

    Objective: To evaluate the AVS effectiveness in depression, anxiety, autonomic disorders and visual dysfunction in PD patients. Background: The severity of non-motor dopa-resistant symptoms in…
  • 2024 International Congress

    Clinical Response and Reduction in Medication Use After Deep Brain Stimulation Surgery in a Cohort of Parkinson’s Disease Patients in Colombia

    T. Lopez Gonzalez, S. Poveda, M. Fonseca, P. Arango, O. Rojas, G. Monsalve, JC. Diez, J. Lobato, O. Bernal Pacheco (Bogotá, Colombia)

    Objective: The objective is to investigate the clinical outcomes and subsequent use of medications in a group of Colombian Patients with DBS Surgery. Background: Parkinson's…
  • 2024 International Congress

    Association between statin use and mortality in Parkinson’s disease

    M. Park, I. Hong, M. Baek (Gwangmyeong, Republic of Korea)

    Objective: To investigate whether usage of statin is associated with decreased mortality in Parkinson’s disease (PD). Background: Large-scale genome sequencing studies of PD have identified…
  • 2024 International Congress

    Deciphering the Role of Auranofin-Loaded Nanoparticles Against Rotenone Model of Parkinson’s Disease: Via GSK-3β/ Nrf2/HO-1 Signaling Pathways

    D. Soni, P. Kumar (Bathinda, India)

    Objective: To investigate the neuroprotective effect of AUF-loaded nanoparticles in animal models of Parkinson's disease by modulating GSK-3β/ Nrf2/HO-1 Signaling Pathways. Background: Parkinson's disease (PD) is…
  • 2024 International Congress

    Immunoproteasome subunits as emerging contributors to neurodegeneration in Parkinson’s Disease

    HD. Nguyen, YE. Kim (Anyang-si, Gyeonggi-do, Republic of Korea)

    Objective: To gain comprehensive contribution of immunoproteasome in central nervous system of Parkinson's Disease Background: Recent investigations have elucidated that, in addition to the classical…
  • 2024 International Congress

    Gut Microbial Metabolites and Future Risk of Parkinson’s Disease: A Metabolome-wide Association Study

    Y. Zhao, Y. Lai, S. Darweesh, B. Bloem, L. Forsgren, J. Hansen, JM. Huerta, M. Guevara, C. Lill, G. Miller, S. Peters, R. Vermeulen (Utrecht, Netherlands)

    Objective: To prospectively investigate the association between plasma microbial metabolites and Parkinson’s disease (PD) risk within a metabolomics framework. Background: Gut microbiota is altered in…
  • 2024 International Congress

    Functionality Analysis of Immunoregulatory Cells Stimulated with Dopaminergic Agonists in People Living with Parkinson’s Disease

    AY. Regalado-Mustafá, DD. álvarez-Luquín, A. Guevara-Salinas, MA. Bravo-Martinez, EJ. Gallegos-Altamirano, CF. álvarez-Hernández, E. Ichikawa-Escamilla, AM. Peralta-Maza, V. Morales-Ruiz, EE. Sevilla-Reyes, JI. Velasco-Velázquez, JE. Estudillo-Hernández, M. Rodríguez-Violante, LV. Adalid-Peralta (Mexico City, Mexico)

    Objective: To evaluate the effect of dopaminergic agonists (DA) on the activation and functionality of regulatory cells in People living with Parkinson's Disease (PwP). Background:…
  • 2024 International Congress

    Higher Putamen Volume Asymmetry with Age-Preserved Volume in Isolated Adult-Onset Cervical Dystonia

    M. Owusu-Ansah, A. Tatenbaum, N. Goldman, SA. Norris (Saint Louis, USA)

    Objective: This study aims to explore the relationship between left and right putamen volumes in cervical dystonia (CD) patients compared to age-matched healthy controls (HC),…
  • 2024 International Congress

    The Next Move in Movement Disorders: Differentiating between Hyperkinetic Movement Disorders using [18F] FDG PET

    J. Dalenberg, D. Peretti, L. Marapin, S. Jonker, E. Timmers, A. Vander Stouwe, M. Tijssen (Groningen, Netherlands)

    Objective: Understanding the differences in brain glucose metabolism between hyperkinetic movement disorders. Background: The Next Move in Movement Disorders (NEMO) study is a research initiative…
  • 2024 International Congress

    Mapping the distribution of neurotransmitters to resting-state functional connectivity in patients with Parkinson’s disease

    W. Li, N. Lao-Kaim, R. Li, A. Martín-Bastida, A. Roussakis, G. Searle, N. Valle-Guzman, V. Dayal, D. Athauda, Z. Kefalopoulou, P. Mahlknecht, A. Church, K. Peall, H. Widner, G. Paul, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

    Objective: To examine the associations between functional connectivity (FC), as measured by resting-state functional magnetic resonance imaging (rs-fMRI), and the spatial distribution of dopamine and…
  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley